• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

FDA clears first point-of-care allergy test device

Article

The Food and Drug Administration granted clearance to market the first point-of-care device to diagnose allergies in the offices with a moderate complexity lab.

The Food and Drug Administration (FDA) granted clearance to market the first point-of-care device to diagnose allergies in the offices with a moderate-complexity lab.

Uppsala, Sweden-based Phadia earned the clearance to sell its ImmunoCAP Rapid System. With the system, physicians who treat patients who have asthma and rhinitis will have semi-quantitative measurements of IgE levels for 10 common inhalant allergens in the United States in about 20 minutes, according to the company.

Retail prices for the ImmunoCAP Rapid System, which has been used in Europe for three years, were not available.

Related Videos